Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor. 2009

Cécile Béguin, and Katharine K Duncan, and Thomas A Munro, and Douglas M Ho, and Wei Xu, and Lee-Yuan Liu-Chen, and William A Carlezon, and Bruce M Cohen
Mailman Research Center, McLean Hospital, Belmont, MA 02478, USA. cbeguin@mclean.harvard.edu

In an effort to find novel agents which selectively target the kappa opioid receptor (KOPR), we modified the furan ring of the highly potent and selective KOPR agonist salvinorin A. Introduction of small substituents at C-16 was well tolerated. 12-epi-Salvinorin A, synthesized in four steps from salvinorin A, was a selective partial agonist at the KOPR. No clear SAR patterns were observed for C-13 aryl ketones. Introducing a hydroxymethylene group between C-12 and the furan ring was tolerated. Small C-13 esters and ethers gave weak KOPR agonists, while all C-13 amides were inactive. Finally, substitution of oxadiazoles for the furan ring abolished affinity for the KOPR. None of the compounds displayed any KOPR antagonism or any affinity for mu or delta opioid receptors.

UI MeSH Term Description Entries
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D017473 Receptors, Opioid, kappa A class of opioid receptors recognized by its pharmacological profile. Kappa opioid receptors bind dynorphins with a higher affinity than endorphins which are themselves preferred to enkephalins. Opioid Receptors, kappa,Receptors, kappa,Receptors, kappa Opioid,kappa Receptors,kappa Opioid Receptor,kappa Receptor,Opioid Receptor, kappa,Receptor, kappa,Receptor, kappa Opioid,kappa Opioid Receptors
D045785 Diterpenes, Clerodane A group of DITERPENES cyclized into 2-rings with a side-chain. Clerodane Diterpene,Clerodane Diterpenoid,Clerodane Diterpenoids,Neoclerodane Diterpene,Neoclerodane Diterpenes,Neoclerodanes,Clerodane,Clerodane Diterpenes,Clerodanes,Diterpene, Clerodane,Diterpene, Neoclerodane,Diterpenes, Neoclerodane,Diterpenoid, Clerodane,Diterpenoids, Clerodane

Related Publications

Cécile Béguin, and Katharine K Duncan, and Thomas A Munro, and Douglas M Ho, and Wei Xu, and Lee-Yuan Liu-Chen, and William A Carlezon, and Bruce M Cohen
January 2006, Arzneimittel-Forschung,
Cécile Béguin, and Katharine K Duncan, and Thomas A Munro, and Douglas M Ho, and Wei Xu, and Lee-Yuan Liu-Chen, and William A Carlezon, and Bruce M Cohen
October 2004, Life sciences,
Cécile Béguin, and Katharine K Duncan, and Thomas A Munro, and Douglas M Ho, and Wei Xu, and Lee-Yuan Liu-Chen, and William A Carlezon, and Bruce M Cohen
September 2002, Proceedings of the National Academy of Sciences of the United States of America,
Cécile Béguin, and Katharine K Duncan, and Thomas A Munro, and Douglas M Ho, and Wei Xu, and Lee-Yuan Liu-Chen, and William A Carlezon, and Bruce M Cohen
July 2007, Journal of the American Chemical Society,
Cécile Béguin, and Katharine K Duncan, and Thomas A Munro, and Douglas M Ho, and Wei Xu, and Lee-Yuan Liu-Chen, and William A Carlezon, and Bruce M Cohen
May 2013, Bioorganic & medicinal chemistry letters,
Cécile Béguin, and Katharine K Duncan, and Thomas A Munro, and Douglas M Ho, and Wei Xu, and Lee-Yuan Liu-Chen, and William A Carlezon, and Bruce M Cohen
January 2006, Pharmacology, biochemistry, and behavior,
Cécile Béguin, and Katharine K Duncan, and Thomas A Munro, and Douglas M Ho, and Wei Xu, and Lee-Yuan Liu-Chen, and William A Carlezon, and Bruce M Cohen
May 2017, Phytochemistry,
Cécile Béguin, and Katharine K Duncan, and Thomas A Munro, and Douglas M Ho, and Wei Xu, and Lee-Yuan Liu-Chen, and William A Carlezon, and Bruce M Cohen
January 2005, Journal of medicinal chemistry,
Cécile Béguin, and Katharine K Duncan, and Thomas A Munro, and Douglas M Ho, and Wei Xu, and Lee-Yuan Liu-Chen, and William A Carlezon, and Bruce M Cohen
January 2008, The Journal of pharmacology and experimental therapeutics,
Cécile Béguin, and Katharine K Duncan, and Thomas A Munro, and Douglas M Ho, and Wei Xu, and Lee-Yuan Liu-Chen, and William A Carlezon, and Bruce M Cohen
April 2016, Brain research,
Copied contents to your clipboard!